 Shanta Zimmer
Concepts (293)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 13 | 2021 | 617 | 1.100 |
Why?
| | Influenza A Virus, H1N1 Subtype | 8 | 2011 | 157 | 0.930 |
Why?
| | Physician-Patient Relations | 3 | 2016 | 588 | 0.660 |
Why?
| | Physicians, Women | 1 | 2020 | 88 | 0.590 |
Why?
| | Vulnerable Populations | 1 | 2020 | 177 | 0.570 |
Why?
| | Coronavirus Infections | 2 | 2023 | 378 | 0.570 |
Why?
| | Neisseria meningitidis | 3 | 2007 | 23 | 0.560 |
Why?
| | Lymphocyte Antigen 96 | 3 | 2008 | 24 | 0.550 |
Why?
| | Communicable Diseases | 1 | 2020 | 163 | 0.550 |
Why?
| | Internship and Residency | 6 | 2019 | 1257 | 0.490 |
Why?
| | Professional Misconduct | 1 | 2016 | 13 | 0.470 |
Why?
| | Meningitis, Meningococcal | 2 | 2006 | 6 | 0.460 |
Why?
| | Pennsylvania | 8 | 2021 | 138 | 0.450 |
Why?
| | Faculty | 1 | 2016 | 149 | 0.440 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 384 | 0.440 |
Why?
| | Meningococcal Vaccines | 2 | 2006 | 58 | 0.440 |
Why?
| | Curriculum | 4 | 2024 | 1060 | 0.420 |
Why?
| | Internal Medicine | 4 | 2018 | 280 | 0.400 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 172 | 0.350 |
Why?
| | Influenza Vaccines | 6 | 2011 | 529 | 0.350 |
Why?
| | Physicians | 3 | 2016 | 940 | 0.330 |
Why?
| | Computer Simulation | 9 | 2012 | 1026 | 0.310 |
Why?
| | Toll-Like Receptor 4 | 4 | 2008 | 276 | 0.300 |
Why?
| | Reassortant Viruses | 1 | 2009 | 8 | 0.300 |
Why?
| | Education, Medical, Graduate | 4 | 2019 | 557 | 0.300 |
Why?
| | Education, Medical, Undergraduate | 1 | 2012 | 207 | 0.300 |
Why?
| | Students, Medical | 2 | 2024 | 375 | 0.300 |
Why?
| | Zoonoses | 1 | 2009 | 36 | 0.290 |
Why?
| | Communicable Diseases, Emerging | 1 | 2009 | 38 | 0.290 |
Why?
| | Lipid A | 3 | 2007 | 28 | 0.280 |
Why?
| | Orthomyxoviridae Infections | 1 | 2009 | 72 | 0.280 |
Why?
| | Respiratory Tract Infections | 2 | 2023 | 398 | 0.260 |
Why?
| | Zygomycosis | 1 | 2007 | 6 | 0.260 |
Why?
| | Cyclosporiasis | 1 | 2007 | 1 | 0.260 |
Why?
| | Dermatomycoses | 1 | 2007 | 8 | 0.260 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2008 | 177 | 0.260 |
Why?
| | Paclitaxel | 1 | 2008 | 256 | 0.250 |
Why?
| | Oxazolidinones | 2 | 2004 | 17 | 0.250 |
Why?
| | Acetamides | 2 | 2004 | 38 | 0.250 |
Why?
| | Thiazoles | 1 | 2007 | 136 | 0.240 |
Why?
| | Sexual and Gender Minorities | 2 | 2022 | 251 | 0.240 |
Why?
| | Gram-Positive Bacterial Infections | 2 | 2005 | 70 | 0.240 |
Why?
| | Drug Hypersensitivity | 1 | 2007 | 90 | 0.230 |
Why?
| | Triazoles | 1 | 2007 | 184 | 0.230 |
Why?
| | Humans | 50 | 2024 | 144957 | 0.230 |
Why?
| | Fungi | 1 | 2007 | 161 | 0.220 |
Why?
| | Leadership | 2 | 2020 | 409 | 0.220 |
Why?
| | Schools | 4 | 2021 | 453 | 0.220 |
Why?
| | History, 21st Century | 2 | 2020 | 219 | 0.220 |
Why?
| | Disease Outbreaks | 5 | 2010 | 422 | 0.220 |
Why?
| | History, 20th Century | 2 | 2020 | 325 | 0.210 |
Why?
| | Exploratory Behavior | 1 | 2024 | 86 | 0.200 |
Why?
| | Medical Tourism | 1 | 2023 | 9 | 0.200 |
Why?
| | Coronavirus NL63, Human | 1 | 2023 | 3 | 0.200 |
Why?
| | Coronavirus OC43, Human | 1 | 2023 | 7 | 0.200 |
Why?
| | Coronavirus 229E, Human | 1 | 2023 | 7 | 0.200 |
Why?
| | Enterococcus faecalis | 1 | 2003 | 29 | 0.200 |
Why?
| | Models, Molecular | 1 | 2008 | 1619 | 0.190 |
Why?
| | Endocarditis, Bacterial | 1 | 2003 | 44 | 0.190 |
Why?
| | Sulfonamides | 1 | 2007 | 581 | 0.190 |
Why?
| | Clinical Clerkship | 1 | 2024 | 111 | 0.190 |
Why?
| | Meningitis | 1 | 2023 | 80 | 0.180 |
Why?
| | Models, Economic | 3 | 2012 | 62 | 0.180 |
Why?
| | Mycobacterium abscessus | 1 | 2023 | 118 | 0.170 |
Why?
| | Pre-Exposure Prophylaxis | 2 | 2022 | 246 | 0.170 |
Why?
| | Viruses | 1 | 2023 | 165 | 0.160 |
Why?
| | Emergency Responders | 1 | 2021 | 37 | 0.160 |
Why?
| | Program Evaluation | 3 | 2019 | 949 | 0.160 |
Why?
| | Crowding | 1 | 2020 | 37 | 0.160 |
Why?
| | Awards and Prizes | 1 | 2020 | 71 | 0.150 |
Why?
| | Shoulder | 1 | 2020 | 105 | 0.150 |
Why?
| | Frail Elderly | 1 | 2020 | 134 | 0.150 |
Why?
| | Prisons | 1 | 2020 | 84 | 0.150 |
Why?
| | Surgery Department, Hospital | 1 | 2018 | 23 | 0.140 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2023 | 366 | 0.140 |
Why?
| | Virus Diseases | 1 | 2021 | 216 | 0.140 |
Why?
| | Evidence-Based Medicine | 2 | 2024 | 732 | 0.140 |
Why?
| | Minority Groups | 1 | 2020 | 282 | 0.140 |
Why?
| | Financing, Organized | 1 | 2018 | 36 | 0.140 |
Why?
| | Nursing Homes | 1 | 2020 | 172 | 0.140 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2018 | 143 | 0.130 |
Why?
| | Faculty, Medical | 2 | 2018 | 303 | 0.130 |
Why?
| | Adult | 18 | 2023 | 40506 | 0.130 |
Why?
| | Point-of-Care Systems | 2 | 2017 | 187 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 286 | 0.130 |
Why?
| | Preceptorship | 1 | 2017 | 67 | 0.130 |
Why?
| | Urban Population | 1 | 2020 | 491 | 0.130 |
Why?
| | Clinical Competence | 3 | 2024 | 1244 | 0.120 |
Why?
| | Population Surveillance | 2 | 2011 | 485 | 0.120 |
Why?
| | Occupational Exposure | 1 | 2020 | 354 | 0.120 |
Why?
| | Societies, Medical | 1 | 2020 | 887 | 0.120 |
Why?
| | Anesthesiology | 1 | 2018 | 175 | 0.110 |
Why?
| | Endotoxins | 2 | 2007 | 221 | 0.110 |
Why?
| | Rural Population | 1 | 2020 | 650 | 0.110 |
Why?
| | Continuity of Patient Care | 1 | 2017 | 292 | 0.110 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 357 | 0.110 |
Why?
| | HIV Infections | 2 | 2022 | 3154 | 0.110 |
Why?
| | Female | 18 | 2022 | 78376 | 0.110 |
Why?
| | Sexual Behavior | 1 | 2019 | 492 | 0.110 |
Why?
| | Antiviral Agents | 2 | 2011 | 768 | 0.110 |
Why?
| | Binding Sites | 2 | 2008 | 1331 | 0.110 |
Why?
| | Recombinant Proteins | 2 | 2008 | 1371 | 0.110 |
Why?
| | Cardiology | 1 | 2017 | 353 | 0.100 |
Why?
| | Anti-HIV Agents | 1 | 2022 | 888 | 0.100 |
Why?
| | United States | 7 | 2020 | 15988 | 0.100 |
Why?
| | Hand Hygiene | 1 | 2013 | 9 | 0.100 |
Why?
| | Work Schedule Tolerance | 1 | 2013 | 51 | 0.100 |
Why?
| | Macrophage Activation | 2 | 2005 | 193 | 0.100 |
Why?
| | Male | 17 | 2022 | 72406 | 0.100 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2013 | 98 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2003 | 1915 | 0.090 |
Why?
| | Macrophages | 4 | 2008 | 1511 | 0.090 |
Why?
| | Receptors, Cell Surface | 2 | 2005 | 377 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2011 | 2147 | 0.090 |
Why?
| | Membrane Glycoproteins | 2 | 2005 | 496 | 0.090 |
Why?
| | Patients | 1 | 2013 | 182 | 0.090 |
Why?
| | Patient Admission | 1 | 2013 | 218 | 0.090 |
Why?
| | Social Support | 1 | 2016 | 652 | 0.090 |
Why?
| | Antibodies, Viral | 2 | 2021 | 672 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1695 | 0.090 |
Why?
| | Surveys and Questionnaires | 3 | 2021 | 6053 | 0.090 |
Why?
| | Poverty Areas | 1 | 2011 | 42 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 2 | 2011 | 2365 | 0.080 |
Why?
| | Guanidines | 1 | 2011 | 41 | 0.080 |
Why?
| | Cyclopentanes | 1 | 2011 | 20 | 0.080 |
Why?
| | Patient Preference | 1 | 2013 | 225 | 0.080 |
Why?
| | Health Care Costs | 2 | 2011 | 427 | 0.080 |
Why?
| | Hemagglutinins | 1 | 2010 | 10 | 0.080 |
Why?
| | Aged | 8 | 2020 | 25947 | 0.080 |
Why?
| | Pneumococcal Infections | 1 | 2011 | 103 | 0.080 |
Why?
| | Clostridium Infections | 1 | 2011 | 74 | 0.080 |
Why?
| | Hospitalization | 1 | 2020 | 2434 | 0.080 |
Why?
| | Quality Improvement | 1 | 2019 | 1291 | 0.080 |
Why?
| | Students | 1 | 2016 | 663 | 0.080 |
Why?
| | Quarantine | 1 | 2010 | 31 | 0.080 |
Why?
| | Occupational Health Services | 1 | 2009 | 37 | 0.080 |
Why?
| | Health Care Rationing | 1 | 2010 | 60 | 0.080 |
Why?
| | Staphylococcal Infections | 2 | 2012 | 390 | 0.080 |
Why?
| | Influenza A Virus, H2N2 Subtype | 1 | 2009 | 1 | 0.080 |
Why?
| | Communication | 1 | 2016 | 967 | 0.080 |
Why?
| | Antigenic Variation | 1 | 2009 | 11 | 0.080 |
Why?
| | Seasons | 2 | 2023 | 556 | 0.070 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 245 | 0.070 |
Why?
| | Antibody Specificity | 1 | 2009 | 181 | 0.070 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 249 | 0.070 |
Why?
| | Asthma | 1 | 2020 | 1768 | 0.070 |
Why?
| | Birds | 1 | 2009 | 92 | 0.070 |
Why?
| | Young Adult | 7 | 2020 | 14126 | 0.070 |
Why?
| | Cross Infection | 1 | 2011 | 262 | 0.070 |
Why?
| | Child | 9 | 2023 | 22657 | 0.070 |
Why?
| | Primary Prevention | 1 | 2010 | 220 | 0.070 |
Why?
| | Disease Management | 1 | 2012 | 647 | 0.070 |
Why?
| | Meningitis, Bacterial | 1 | 2008 | 45 | 0.070 |
Why?
| | Carbohydrate Conformation | 1 | 2007 | 15 | 0.070 |
Why?
| | Genome, Viral | 1 | 2009 | 218 | 0.070 |
Why?
| | Pichia | 1 | 2007 | 19 | 0.070 |
Why?
| | Protein Structure, Secondary | 1 | 2008 | 369 | 0.060 |
Why?
| | Cell Line | 3 | 2008 | 2882 | 0.060 |
Why?
| | Child, Preschool | 7 | 2021 | 11799 | 0.060 |
Why?
| | Cyclospora | 1 | 2007 | 1 | 0.060 |
Why?
| | Antiparasitic Agents | 1 | 2007 | 4 | 0.060 |
Why?
| | Nitro Compounds | 1 | 2007 | 8 | 0.060 |
Why?
| | Surface Properties | 1 | 2008 | 410 | 0.060 |
Why?
| | Tubulin | 1 | 2008 | 147 | 0.060 |
Why?
| | Species Specificity | 1 | 2008 | 574 | 0.060 |
Why?
| | Linezolid | 2 | 2004 | 25 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2011 | 462 | 0.060 |
Why?
| | District of Columbia | 3 | 2011 | 36 | 0.060 |
Why?
| | Swine | 1 | 2009 | 833 | 0.060 |
Why?
| | Neonatal Screening | 1 | 2008 | 178 | 0.060 |
Why?
| | Chronic Disease | 1 | 2012 | 1813 | 0.060 |
Why?
| | Antifungal Agents | 1 | 2007 | 149 | 0.060 |
Why?
| | Protein Structure, Tertiary | 1 | 2008 | 862 | 0.060 |
Why?
| | Phylogeny | 1 | 2010 | 1019 | 0.060 |
Why?
| | Vancomycin Resistance | 1 | 2005 | 16 | 0.060 |
Why?
| | Enterococcus | 1 | 2005 | 22 | 0.060 |
Why?
| | Antigens, Differentiation | 1 | 2005 | 77 | 0.060 |
Why?
| | Evolution, Molecular | 1 | 2009 | 515 | 0.060 |
Why?
| | Adolescent | 7 | 2022 | 22453 | 0.060 |
Why?
| | Transfection | 1 | 2007 | 940 | 0.050 |
Why?
| | Efficiency | 2 | 2019 | 104 | 0.050 |
Why?
| | Vaccines, Conjugate | 1 | 2004 | 60 | 0.050 |
Why?
| | Receptors, Immunologic | 1 | 2005 | 206 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2008 | 2032 | 0.050 |
Why?
| | Lipopolysaccharides | 2 | 2005 | 863 | 0.050 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2008 | 1217 | 0.050 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2004 | 87 | 0.050 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2004 | 133 | 0.050 |
Why?
| | Animals | 5 | 2009 | 38109 | 0.050 |
Why?
| | Middle Aged | 9 | 2021 | 35928 | 0.050 |
Why?
| | Bacteremia | 1 | 2005 | 221 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2931 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2011 | 1099 | 0.050 |
Why?
| | Odds Ratio | 2 | 2021 | 1077 | 0.050 |
Why?
| | Aged, 80 and over | 4 | 2020 | 8279 | 0.050 |
Why?
| | Models, Statistical | 3 | 2011 | 682 | 0.050 |
Why?
| | Protein Binding | 1 | 2008 | 2276 | 0.040 |
Why?
| | Anti-Infective Agents | 1 | 2004 | 242 | 0.040 |
Why?
| | Influenza B virus | 1 | 2021 | 47 | 0.040 |
Why?
| | Contact Tracing | 1 | 2021 | 26 | 0.040 |
Why?
| | Infant | 4 | 2012 | 10039 | 0.040 |
Why?
| | Monte Carlo Method | 2 | 2011 | 155 | 0.040 |
Why?
| | Absenteeism | 1 | 2021 | 53 | 0.040 |
Why?
| | Membrane Cofactor Protein | 2 | 2011 | 14 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2022 | 222 | 0.040 |
Why?
| | Learning | 1 | 2024 | 452 | 0.040 |
Why?
| | Ecology | 1 | 2021 | 121 | 0.040 |
Why?
| | Risk Factors | 3 | 2021 | 10792 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2007 | 4155 | 0.040 |
Why?
| | Stem Cells | 1 | 2023 | 627 | 0.040 |
Why?
| | Regression Analysis | 1 | 2021 | 1003 | 0.040 |
Why?
| | Temperature | 1 | 2021 | 679 | 0.030 |
Why?
| | Cost-Benefit Analysis | 2 | 2011 | 636 | 0.030 |
Why?
| | Diabetes Mellitus | 1 | 2007 | 1098 | 0.030 |
Why?
| | Schools, Medical | 1 | 2019 | 157 | 0.030 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 320 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1054 | 0.030 |
Why?
| | Medication Adherence | 1 | 2022 | 539 | 0.030 |
Why?
| | Feedback | 1 | 2018 | 181 | 0.030 |
Why?
| | Models, Educational | 1 | 2017 | 89 | 0.030 |
Why?
| | Diagnostic Errors | 1 | 2018 | 175 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2021 | 893 | 0.030 |
Why?
| | Cohort Studies | 2 | 2021 | 5965 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2020 | 708 | 0.030 |
Why?
| | Mice | 3 | 2008 | 18365 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 2119 | 0.030 |
Why?
| | Focus Groups | 1 | 2018 | 573 | 0.030 |
Why?
| | Educational Measurement | 1 | 2018 | 326 | 0.030 |
Why?
| | Infant, Newborn | 3 | 2012 | 6434 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2020 | 916 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 359 | 0.030 |
Why?
| | Age Factors | 1 | 2021 | 3335 | 0.020 |
Why?
| | Toll-Like Receptors | 2 | 2005 | 194 | 0.020 |
Why?
| | Biomedical Research | 1 | 2019 | 710 | 0.020 |
Why?
| | Sex Factors | 1 | 2018 | 2114 | 0.020 |
Why?
| | Body Mass Index | 1 | 2020 | 2438 | 0.020 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2011 | 29 | 0.020 |
Why?
| | Receptors, Interleukin-1 Type I | 1 | 2011 | 25 | 0.020 |
Why?
| | Signal Transduction | 1 | 2005 | 5233 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2017 | 853 | 0.020 |
Why?
| | Acids, Carbocyclic | 1 | 2011 | 1 | 0.020 |
Why?
| | Decision Trees | 1 | 2011 | 81 | 0.020 |
Why?
| | Data Collection | 1 | 2013 | 635 | 0.020 |
Why?
| | Stochastic Processes | 1 | 2011 | 71 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4564 | 0.020 |
Why?
| | Quality-Adjusted Life Years | 1 | 2011 | 121 | 0.020 |
Why?
| | Gene Frequency | 1 | 2011 | 481 | 0.020 |
Why?
| | Diarrhea | 1 | 2011 | 192 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2011 | 333 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2012 | 174 | 0.020 |
Why?
| | Attitude to Health | 1 | 2013 | 436 | 0.020 |
Why?
| | Mass Vaccination | 1 | 2009 | 18 | 0.020 |
Why?
| | Calibration | 1 | 2010 | 151 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 423 | 0.020 |
Why?
| | Cost of Illness | 1 | 2012 | 321 | 0.020 |
Why?
| | Streptococcus pneumoniae | 1 | 2011 | 177 | 0.020 |
Why?
| | Immunization Programs | 1 | 2011 | 194 | 0.020 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 140 | 0.020 |
Why?
| | Travel | 1 | 2010 | 136 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1416 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2011 | 371 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2022 | 17101 | 0.020 |
Why?
| | Workplace | 1 | 2009 | 274 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2010 | 378 | 0.020 |
Why?
| | Occupational Health | 1 | 2009 | 209 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2011 | 1327 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2011 | 456 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1835 | 0.020 |
Why?
| | Pilot Projects | 1 | 2011 | 1890 | 0.010 |
Why?
| | Environmental Exposure | 1 | 2010 | 590 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2005 | 251 | 0.010 |
Why?
| | Kidney Failure, Chronic | 1 | 2011 | 598 | 0.010 |
Why?
| | Gram-Negative Bacteria | 1 | 2005 | 81 | 0.010 |
Why?
| | DNA | 1 | 2011 | 1464 | 0.010 |
Why?
| | Growth | 1 | 2004 | 49 | 0.010 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2005 | 116 | 0.010 |
Why?
| | Incidence | 1 | 2011 | 2883 | 0.010 |
Why?
| | Sugar Acids | 1 | 2004 | 4 | 0.010 |
Why?
| | Respiratory Burst | 1 | 2004 | 18 | 0.010 |
Why?
| | U937 Cells | 1 | 2004 | 27 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2008 | 1095 | 0.010 |
Why?
| | Antigens, Surface | 1 | 2004 | 157 | 0.010 |
Why?
| | Toll-Like Receptor 2 | 1 | 2004 | 126 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1822 | 0.010 |
Why?
| | Vaccination | 1 | 2011 | 1423 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 11695 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2004 | 570 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2005 | 428 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 5872 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2008 | 3608 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2005 | 897 | 0.010 |
Why?
| | Time Factors | 1 | 2009 | 7183 | 0.010 |
Why?
| | Cytokines | 1 | 2005 | 2065 | 0.010 |
Why?
|
|
Zimmer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|